Professional News Dissemination Services

Monday, March 2, 2015

RiceBran Technologies and Medicus Research Release Claims Substantiation Analysis of the Health Benefits of RBT's Patented Rice Bran Derivatives

Independent clinical studies and research demonstrate benefits across numerous health and wellness categories including lowering cholesterol, reducing hyperglycemia and improving insulin levels and insulin sensitivity

SCOTTSDALE, Ariz., March 2, 2015 /PRNewswire via COMTEX/ -- RiceBran Technologies (NASDAQ: RIBT and RIBTW) ("RBT"), a global leader in the production and marketing of value added products derived from rice bran, today announced the release of a claims substantiation analysis of the health benefits of RBT's proprietary rice bran based ingredients conducted by Medicus Research.

RBT contracted Medicus Research, the premier contract research organization for the Dietary Supplement, Functional Foods and Botanical Drug industries, to perform a comprehensive analysis of independent studies conducted on behalf of RBT to substantiate numerous important health claims for its proprietary and process patented rice bran derivatives and products.

The research from Medicus substantiates that RBT's RiBran(TM) and RiSolubles products reduce hyperglycemia; improves insulin levels and insulin sensitivity; and increases adiponectin levels. The research also cites scientific evidence indicating that the Company's RiFiber(TM) product reduces total cholesterol, LDL cholesterol and triglycerides; reduces absorption of cholesterol; and reduces plasma lipid and lipoprotein cholesterol.

The full report as well as links to clinical study findings can be found on RBT's home page at .

W. John Short, CEO & President of RBT commented, "As the consumer package goods industry focuses billions of dollars on healthy whole food nutrition, the ability to provide ingredients that can result in important front of label claims for these new products differentiates RBT from our competitors. Medicus Research is widely considered to be the leading provider of research and clinical trials for healthy, natural products and functional foods. We are excited that the team at Medicus has substantiated the health benefits of our rice bran based products. We plan to pursue additional studies with Medicus going forward."

Dr. Jay Udani, co-founder and CEO of Medicus Research noted, "RiceBran Technologies proprietary ingredients and the active components of these ingredients have been the subject of numerous studies which, when the evidence is combined, appear to be able to substantiate claims related to the management of healthy lipids, glucose, and insulin. We look forward to working with RBT on additional projects in the future."

About Medicus Research

Medicus Research is the internationally renowned contract research organization specializing in the study of dietary supplements, functional foods, medical foods, botanical drugs and cosmeceuticals. The California-based CRO was founded 15 years ago by Dr. Jay Udani. As a board-certified internist at Cedars-Sinai Medical Center in Beverly Hills, Dr. Udani was among the first physicians in America to become a certified physician investigator for clinical trials. He was passionate about the study of natural health products as an alternative to traditional pharmaceuticals. Today, Dr. Udani's company is considered the leader in this industry. Medicus Research has designed, executed and analyzed more than 200 Phase I - IV clinical trials. The company designs its clinical trials to guarantee that its studies are structure/function compliant and follow strict guidelines issued by FTC, FDA, and EFSA for subject population and endpoint selection. Medicus Research has established GCP and FDA compliant SOPs, internal QA processes, and proprietary management technology systems which ensure the highest quality for all aspects of the study process.

About RiceBran Technologies

RiceBran Technologies is a human food ingredient and functional food company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. RiceBran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in our filings with the SEC and by visiting our website at .

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements about RiceBran Technologies' expectations regarding introduction of new products for the craft brewing industry. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties. RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies' filings with the Securities and Exchange Commission, including its most recent periodic reports.

Investor Contact:

Ascendant Partners, LLCFred Sommer+(732)

To view the original version on PR Newswire, visit:

SOURCE RiceBran Technologies

FN Media Group LLC (FNMG) owns and operates (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For recent services performed FNMG has been compensated one thousand nine hundred dollars for RiceBran Technologies news coverage by the Company.  FNMG HOLDS NO SHARES OF RiceBran Technologies.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

No comments:

Post a Comment